Kwality Pharmaceuticals Ltd
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]
- Market Cap ₹ 899 Cr.
- Current Price ₹ 866
- High / Low ₹ 961 / 356
- Stock P/E 26.4
- Book Value ₹ 232
- Dividend Yield 0.00 %
- ROCE 15.9 %
- ROE 13.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 30.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.4%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 98.5 to 136 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
60 | 52 | 74 | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 307 | 340 | |
56 | 49 | 69 | 89 | 126 | 150 | 125 | 233 | 285 | 190 | 241 | 266 | |
Operating Profit | 4 | 3 | 5 | 9 | 12 | 16 | 14 | 29 | 172 | 61 | 66 | 74 |
OPM % | 6% | 6% | 7% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% |
0 | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | -5 | |
Interest | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 11 |
Depreciation | 1 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 19 |
Profit before tax | 2 | 1 | 2 | 6 | 7 | 11 | 11 | 21 | 162 | 26 | 31 | 39 |
Tax % | 47% | 41% | 48% | 42% | 39% | 31% | 25% | 30% | 26% | 25% | 24% | |
1 | 1 | 1 | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 24 | 29 | |
EPS in Rs | 0.93 | 0.92 | 1.55 | 3.23 | 4.39 | 7.28 | 8.02 | 14.60 | 115.64 | 18.67 | 22.94 | 27.83 |
Dividend Payout % | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 13% |
3 Years: | 5% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | 41% |
5 Years: | 31% |
3 Years: | 25% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 98% |
3 Years: | 4% |
1 Year: | 123% |
Return on Equity | |
---|---|
10 Years: | 30% |
5 Years: | 33% |
3 Years: | 34% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 13 | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 231 |
6 | 8 | 13 | 19 | 26 | 29 | 35 | 41 | 54 | 90 | 98 | 103 | |
12 | 10 | 17 | 26 | 40 | 39 | 52 | 64 | 105 | 70 | 72 | 50 | |
Total Liabilities | 35 | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 394 |
13 | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 120 | 139 | 138 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 |
Investments | 1 | 1 | 2 | 4 | 5 | 5 | 4 | 5 | 0 | 0 | 0 | 0 |
22 | 24 | 37 | 50 | 70 | 71 | 86 | 102 | 237 | 226 | 255 | 256 | |
Total Assets | 35 | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 394 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | |
-3 | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | |
3 | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | |
Net Cash Flow | -1 | 1 | 0 | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 41 | 63 | 89 | 84 | 98 | 84 | 79 | 50 | 55 | 104 | 136 |
Inventory Days | 58 | 61 | 67 | 71 | 54 | 34 | 94 | 38 | 97 | 310 | 187 |
Days Payable | 58 | 40 | 63 | 65 | 80 | 52 | 96 | 58 | 63 | 117 | 106 |
Cash Conversion Cycle | 42 | 85 | 93 | 90 | 73 | 67 | 77 | 30 | 90 | 297 | 217 |
Working Capital Days | 61 | 81 | 89 | 76 | 74 | 61 | 99 | 47 | 87 | 209 | 194 |
ROCE % | 9% | 13% | 19% | 19% | 22% | 18% | 26% | 98% | 19% | 16% |
Documents
Announcements
-
Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From Greece
6 Nov - Approval for Leuprorelin Acetate marks entry into Europe.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Nov - NEWSPAPER PUBLICATION OF RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024.
-
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
30 Oct - Approved unaudited financial results for Q2 FY25.
- Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024 30 Oct
-
Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.
22 Oct - Board meeting scheduled to approve financial results.
Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations